Shruti Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shruti Gupta has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Kiran Kumar Tejavath
Central University of Rajasthan
6 shared publications - Khushhal Rathore
Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandarsindri, India
3 shared publications - Hemlata Hemlata
Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India
2 shared publications - Harshita Tak
Department of Sports Bio-Sciences, School of Sports Science MYAS-CURAJ, Central University of Rajasthan
1 shared publication - Hemanth Naick Banavath
Central University of Rajasthan, Rajasthan, India
1 shared publication Kishori G Apte
1 shared publication
Latest Publications
- 28 May 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (6)
Multifunctional PLGA Nanoparticles: pH-Triggered Drug Release for Pancreatic Ductal Adenocarcinoma
- 28 May 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (6)
Multifunctional PLGA Nanoparticles: pH-Triggered Drug Release for Pancreatic Ductal Adenocarcinoma
- 17 February 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (2) , 46
Understanding cytotoxicity induction by plumbagin in pancreatic ductal adenocarcinoma using network pharmacology, bioinformatic and in-vitro study
Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a very poor prognosis, which is bolstered by its resistance and pathogenesis. Quest for PDAC treatments has not left any stones unturned. A well-known naphthoquinone found in many foods, plumbagin (PLGN) demonstrated effectiveness in treating cancer, arthritis, dysmenorrhea, and injuries. We hypothesize therapeutic advantages of PLGN in PDAC and used web resources to assist us identify the targets of PLGN in order to test the idea. After that, in-vitro studies were carried out to comprehend PLGN impacts on two PDAC cell lines. Further, drug combination with PLGN and pre-sensitization by PLGN was also carried out. Findings from network pharmacology investigations revealed PLGN’s targets in PDAC, indicating effect on PDAC survival by targeting crucial signalling. In-vitro tests demonstrated dose-dependent cytotoxicity of PLGN, with IC50 values for Panc-1 and Mia-PaCa-2 cells after 48 h were 2.89 ± 0.42µM and 13.10 ± 0.76µM, respectively. Dox-PLGN and Gem-PLGN combination treatment had antagonistic effects, although doxorubicin’s impact was amplified by PLGN pre-sensitization. The EMT transition and genes that cause resistance were the primary pathways impacted by PLGN therapy that enhance Dox effect. Analysis of gene expression and ROS production demonstrated that PLGN had a different effect on both cell lines. Overall, PLGN shows promise as a pre-sensitizing natural substance for PDAC treatment, promoting more research on its effectiveness, tolerability, and possible incorporation into current chemotherapy regimens. Graphical abstract
- 17 February 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (2) , 46
Understanding cytotoxicity induction by plumbagin in pancreatic ductal adenocarcinoma using network pharmacology, bioinformatic and in-vitro study
Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a very poor prognosis, which is bolstered by its resistance and pathogenesis. Quest for PDAC treatments has not left any stones unturned. A well-known naphthoquinone found in many foods, plumbagin (PLGN) demonstrated effectiveness in treating cancer, arthritis, dysmenorrhea, and injuries. We hypothesize therapeutic advantages of PLGN in PDAC and used web resources to assist us identify the targets of PLGN in order to test the idea. After that, in-vitro studies were carried out to comprehend PLGN impacts on two PDAC cell lines. Further, drug combination with PLGN and pre-sensitization by PLGN was also carried out. Findings from network pharmacology investigations revealed PLGN’s targets in PDAC, indicating effect on PDAC survival by targeting crucial signalling. In-vitro tests demonstrated dose-dependent cytotoxicity of PLGN, with IC50 values for Panc-1 and Mia-PaCa-2 cells after 48 h were 2.89 ± 0.42µM and 13.10 ± 0.76µM, respectively. Dox-PLGN and Gem-PLGN combination treatment had antagonistic effects, although doxorubicin’s impact was amplified by PLGN pre-sensitization. The EMT transition and genes that cause resistance were the primary pathways impacted by PLGN therapy that enhance Dox effect. Analysis of gene expression and ROS production demonstrated that PLGN had a different effect on both cell lines. Overall, PLGN shows promise as a pre-sensitizing natural substance for PDAC treatment, promoting more research on its effectiveness, tolerability, and possible incorporation into current chemotherapy regimens. Graphical abstract
- Open Access
- 14 January 2026
- Published by Springer Nature in Research Square
Understanding cytotoxicity induction by plumbagin in pancreatic ductal adenocarcinoma using network pharmacology, bioinformatic and in-vitro study
Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a very poor prognosis, which is bolstered by its resistance and pathogenesis. Quest for PDAC treatments has not left any stones unturned. A well-known naphthoquinone found in many foods, plumbagin demonstrated effectiveness in treating cancer, arthritis, dysmenorrhea, and injuries. We hypothesize therapeutic advantages of PLGN in PDAC and used web resources to assist us identify the targets of PLGN in order to test the idea. After that, in-vitro studies were carried out to comprehend PLGN impacts on two PDAC cell lines. Further, drug combination with PLGN and pre-sensitization by PLGN was also carried out. Findings from network pharmacology investigations revealed PLGN's targets in PDAC, indicating effect on PDAC survival by targeting crucial signalling. In-vitro tests demonstrated dose-dependent cytotoxicity of PLGN, with IC 50 values for Panc-1 and Mia-PaCa-2 of 2.89 ± 0.42µM and 13.10 ± 0.76µM, respectively. Dox-PLGN and Gem-PLGN combination treatment had antagonistic effects, although doxorubicin's impact was amplified by PLGN pre-sensitization. The EMT transition and genes that cause resistance were the primary pathways impacted by PLGN therapy that enhance Dox effect. Analysis of gene expression and ROS production demonstrated that PLGN had a different effect on both cell lines.
- 14 January 2026
- Published by Springer Nature in Research Square
Open AccessUnderstanding cytotoxicity induction by plumbagin in pancreatic ductal adenocarcinoma using network pharmacology, bioinformatic and in-vitro study
Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a very poor prognosis, which is bolstered by its resistance and pathogenesis. Quest for PDAC treatments has not left any stones unturned. A well-known naphthoquinone found in many foods, plumbagin demonstrated effectiveness in treating cancer, arthritis, dysmenorrhea, and injuries. We hypothesize therapeutic advantages of PLGN in PDAC and used web resources to assist us identify the targets of PLGN in order to test the idea. After that, in-vitro studies were carried out to comprehend PLGN impacts on two PDAC cell lines. Further, drug combination with PLGN and pre-sensitization by PLGN was also carried out. Findings from network pharmacology investigations revealed PLGN's targets in PDAC, indicating effect on PDAC survival by targeting crucial signalling. In-vitro tests demonstrated dose-dependent cytotoxicity of PLGN, with IC 50 values for Panc-1 and Mia-PaCa-2 of 2.89 ± 0.42µM and 13.10 ± 0.76µM, respectively. Dox-PLGN and Gem-PLGN combination treatment had antagonistic effects, although doxorubicin's impact was amplified by PLGN pre-sensitization. The EMT transition and genes that cause resistance were the primary pathways impacted by PLGN therapy that enhance Dox effect. Analysis of gene expression and ROS production demonstrated that PLGN had a different effect on both cell lines.
- 22 February 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (15) , 8319-8333
Caffeic acid, a dietary polyphenol, pre-sensitizes pancreatic ductal adenocarcinoma to chemotherapeutic drug
Resistance to chemotherapeutics is an eminent cause that leads to search for options that help in diminution of pancreatic ductal adenocarcinoma (PDAC) by overcoming resistance issues. Caffeic acid (CFA), a polyphenol occurring in many dietary foods, is known to show antidiabetic and anticancer properties potential. To unveil the effect of CFA on PDAC, we carried out this research in PDAC cells, following which we checked the combination effect of CFA and chemotherapeutics and pre-sensitization effects of CFA. Multitudinous web-based approaches were applied for identifying CFA targets in PDAC and then getting their interconnections. Subsequently, we manifested CFA effects by in-vitro analysis showing IC50 concentrations of 37.37 and 15.06 µM on Panc-1 and Mia-PaCa-2, respectively. The combination index of CFA with different drugs was explored which showed the antagonistic effects of combination treatment leading to further investigation of the pre-sensitizing effects. CFA pre-sensitization reduced IC50 concentration of doxorubicin in both PDAC cell lines which also triggered ROS generation determined by 2',7'-dichlorofluorescin diacetate assay. The differential gene expression analysis after CFA treatment showed discrete genes affected in both cells, i.e. N-Cad and Cas9 in Panc-1 and Pi3K/AkT/mTOR along with p53 in Mia-PaCa-2. Collectively, this study investigated the role of CFA as PDAC therapeutics and explored the mechanism in mitigating resistance of PDAC by sensitizing to chemotherapeutics.Communicated by Ramaswamy H. Sarma.
- 22 February 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (15) , 8319-8333
Caffeic acid, a dietary polyphenol, pre-sensitizes pancreatic ductal adenocarcinoma to chemotherapeutic drug
Resistance to chemotherapeutics is an eminent cause that leads to search for options that help in diminution of pancreatic ductal adenocarcinoma (PDAC) by overcoming resistance issues. Caffeic acid (CFA), a polyphenol occurring in many dietary foods, is known to show antidiabetic and anticancer properties potential. To unveil the effect of CFA on PDAC, we carried out this research in PDAC cells, following which we checked the combination effect of CFA and chemotherapeutics and pre-sensitization effects of CFA. Multitudinous web-based approaches were applied for identifying CFA targets in PDAC and then getting their interconnections. Subsequently, we manifested CFA effects by in-vitro analysis showing IC50 concentrations of 37.37 and 15.06 µM on Panc-1 and Mia-PaCa-2, respectively. The combination index of CFA with different drugs was explored which showed the antagonistic effects of combination treatment leading to further investigation of the pre-sensitizing effects. CFA pre-sensitization reduced IC50 concentration of doxorubicin in both PDAC cell lines which also triggered ROS generation determined by 2',7'-dichlorofluorescin diacetate assay. The differential gene expression analysis after CFA treatment showed discrete genes affected in both cells, i.e. N-Cad and Cas9 in Panc-1 and Pi3K/AkT/mTOR along with p53 in Mia-PaCa-2. Collectively, this study investigated the role of CFA as PDAC therapeutics and explored the mechanism in mitigating resistance of PDAC by sensitizing to chemotherapeutics.Communicated by Ramaswamy H. Sarma.
- Open Access
- 6 April 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (15) , 10383-10395
ROS-Mediated Apoptosis Induced by BSA Nanospheres Encapsulated with Fruit Extract of Cucumis prophetarum in Various Human Cancer Cell Lines
- 6 April 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (15) , 10383-10395
Open AccessROS-Mediated Apoptosis Induced by BSA Nanospheres Encapsulated with Fruit Extract of Cucumis prophetarum in Various Human Cancer Cell Lines
- Open Access
- 25 August 2020
- Published by Beilstein Institut in Beilstein Archives
- Vol. 2020 (1) , 95
Synthesis, characterization and comparative anticancer potential of phytosynthesized mono and bimetallic nanoparticles using Moringa oleifera aqueous leaf extract.
In this article we bring up facile one-step phytosynthesis of Silver (Ag), Gold (Au) and Ag/Au bimetallic nanoparticles by reduction of Silver nitrate and Tetrachloroauric acid solution, using aqueous leaf extract of Moringa oleifera. Physical characterization was done using different techniques including UV-Visible spectroscopy, FT-IR Spectroscopic Analysis, DLS, Zeta Potential, XRD, TEM and EDAX. These nanoparticles were evaluated for their cytotoxicity against human hepatocellular carcinoma cells (HepG2) and breast cancer cell line (MDA-MB-231 and MCF-7). Our data suggest these phytosynthesized nanoparticles showed a dose-dependent cytotoxic effect on all the cancer cell lines. However, AuNPs is seen to have higher cytotoxic potential with IC50 value in the range of 9.20-21.46µg/ml compared to that of Bimetallic NPs (Ag-Au NPs) with IC50 value of 37.22-49.94µg/ml. Whereas, Silver NPs (AgNPs) didn’t show cytotoxic activity upto 60µg/ml in all the three cell lines for 24hrs. Hence, this study supports the effectiveness of phytosynthesized AuNPs for the development of anticancer agents.
- 25 August 2020
- Published by Beilstein Institut in Beilstein Archives
- Vol. 2020 (1) , 95
Open AccessSynthesis, characterization and comparative anticancer potential of phytosynthesized mono and bimetallic nanoparticles using Moringa oleifera aqueous leaf extract.
In this article we bring up facile one-step phytosynthesis of Silver (Ag), Gold (Au) and Ag/Au bimetallic nanoparticles by reduction of Silver nitrate and Tetrachloroauric acid solution, using aqueous leaf extract of Moringa oleifera. Physical characterization was done using different techniques including UV-Visible spectroscopy, FT-IR Spectroscopic Analysis, DLS, Zeta Potential, XRD, TEM and EDAX. These nanoparticles were evaluated for their cytotoxicity against human hepatocellular carcinoma cells (HepG2) and breast cancer cell line (MDA-MB-231 and MCF-7). Our data suggest these phytosynthesized nanoparticles showed a dose-dependent cytotoxic effect on all the cancer cell lines. However, AuNPs is seen to have higher cytotoxic potential with IC50 value in the range of 9.20-21.46µg/ml compared to that of Bimetallic NPs (Ag-Au NPs) with IC50 value of 37.22-49.94µg/ml. Whereas, Silver NPs (AgNPs) didn’t show cytotoxic activity upto 60µg/ml in all the three cell lines for 24hrs. Hence, this study supports the effectiveness of phytosynthesized AuNPs for the development of anticancer agents.
- Open Access
- 10 April 2018
- Published by BioMed Research Publishers in The Journal of Phytopharmacology
- Vol. 7 (2) , 191-198
Evaluation of phytochemical, antioxidant and cytotoxic potential of Sesbania grandiflora Linn.
Sesbania grandiflora Linn. is perennial branching, small erect quick-growing short-lived soft-wooded tree, mostly cultivated in southeast Asian countries including India and grows primarily in hot, humid environments. This study investigated on phytochemical values- total phenolic flavonoid, tannins and saponin contents for Sesbania grandiflora leaf extracts. The total antioxidant capacity, DPPH, reducing power, superoxide scavenging and Iron chelating effects were examined by established methods. In-vitro cytotoxicity by brine shrimp bioassay. Both the extracts of Sesbania grandiflora were found to possess moderate to high amounts of phytochemical contents. The total phenolic, flavonoid and saponin contents were found significantly higher in EQSG whereas tannins were more in AQSG. The EQSG and AQSG possessed low IC50 for H2O2 Scavenging (32.9, 27.3µg/ml), TAC (35.6, 41.8µg/ml) and moderate for DPPH (114.9, 113µg/ml) and reducing power (176.3, 181.6µg/ml) respectively. The Brine shrimp lethality bioassay showed a significantly high LC50 value with EQSG (10313µg/ml) and AQSG (12773µg/ml) compared to cyclophosphamide (110µg/ml) in cytotoxic assay. The results evidenced the potential of Sesbania grandiflora Linn. as potent drug with antioxidant and cytotoxic activity and could be useful for preparation of nutraceuticals for pharmaceutical use in the treatment of various human diseases and its complications.
- 10 April 2018
- Published by BioMed Research Publishers in The Journal of Phytopharmacology
- Vol. 7 (2) , 191-198
Open AccessEvaluation of phytochemical, antioxidant and cytotoxic potential of Sesbania grandiflora Linn.
Sesbania grandiflora Linn. is perennial branching, small erect quick-growing short-lived soft-wooded tree, mostly cultivated in southeast Asian countries including India and grows primarily in hot, humid environments. This study investigated on phytochemical values- total phenolic flavonoid, tannins and saponin contents for Sesbania grandiflora leaf extracts. The total antioxidant capacity, DPPH, reducing power, superoxide scavenging and Iron chelating effects were examined by established methods. In-vitro cytotoxicity by brine shrimp bioassay. Both the extracts of Sesbania grandiflora were found to possess moderate to high amounts of phytochemical contents. The total phenolic, flavonoid and saponin contents were found significantly higher in EQSG whereas tannins were more in AQSG. The EQSG and AQSG possessed low IC50 for H2O2 Scavenging (32.9, 27.3µg/ml), TAC (35.6, 41.8µg/ml) and moderate for DPPH (114.9, 113µg/ml) and reducing power (176.3, 181.6µg/ml) respectively. The Brine shrimp lethality bioassay showed a significantly high LC50 value with EQSG (10313µg/ml) and AQSG (12773µg/ml) compared to cyclophosphamide (110µg/ml) in cytotoxic assay. The results evidenced the potential of Sesbania grandiflora Linn. as potent drug with antioxidant and cytotoxic activity and could be useful for preparation of nutraceuticals for pharmaceutical use in the treatment of various human diseases and its complications.